Background

The first phase of the RESOLUTION clinical trial showed that 12 weeks of utilizing this IV treatment for severe migraines—specifically eptinezumab (a targeted, preventive IV medication)—successfully reduced migraine frequency, severity, and overall disease burden while improving quality of life. This treatment was given to adults dealing with both Chronic Migraine (CM) and Medication-Overuse Headache (MOH) who also received basic patient education.

This summary presents the extended 24-week results regarding how well the treatment worked and its overall safety.

How the Study Was Done

RESOLUTION was a rigorous, international clinical trial split into two back-to-back parts:

• Weeks 1–12 (The Comparison Phase): Adults aged 18–75 with chronic migraines and medication-overuse headaches received a brief educational session about medication overuse. They were then randomly assigned to two groups: one group received an IV infusion of eptinezumab (100 mg) and the other received a placebo (a non-active treatment).
• Weeks 13–24 (The Extension Phase): At the 12-week mark, all participants received an infusion of eptinezumab 100 mg, allowing researchers to observe the long-term effects.

Throughout the entire 24 weeks, researchers tracked changes in monthly migraine days, total headache days, how often patients needed daily rescue medications, average daily pain levels, and how many patients successfully dropped below the clinical thresholds for chronic migraine and medication-overuse diagnoses. They also monitored overall quality of life and any side effects.

Study Results

• High Completion Rates: Out of 608 randomized participants, an overwhelming majority (97.5%) moved on to receive eptinezumab in the second half of the study, and 96.1% completed the entire 24-week trial.
• Sustained Relief: For patients who started on eptinezumab from day one, the initial reductions in migraine frequency and the improvements in daily quality of life were successfully maintained all the way through week 24.
• Catching Up Fast: Participants who originally started on the placebo and switched to eptinezumab at week 12 experienced rapid improvements, reaching similar levels of relief by the end of the study.
• Proven Safety Profile: The treatment was well tolerated. The percentage of patients experiencing side effects during the second half of the study was low and very similar between the two groups—30% for those who received eptinezumab the whole time, and 34% for those who switched from placebo to eptinezumab. No new or unexpected safety concerns were found.

Conclusion

For individuals dealing with chronic migraines and rebound headaches, pairing a brief educational session with a second eptinezumab infusion successfully extends relief and improves quality of life for up to 24 weeks. Because the treatment is highly effective and well tolerated, researchers concluded that combining two infusions of eptinezumab with patient education is a highly reasonable first approach for treating these overlapping headache conditions.